The results of the Application of the Micronized Purified Flavonoid Fraction for the Treatment of Secondary Varicose Veins in the Small Pelvis

Flebologiia ◽  
2015 ◽  
Vol 9 (3) ◽  
pp. 34 ◽  
Author(s):  
Yu. T. Tsukanov ◽  
A. Yu. Tsukanov ◽  
E. G. Levdansky
Keyword(s):  
Varicose Veins ◽  
Micronized Purified Flavonoid Fraction ◽  
Flavonoid Fraction

scholarly journals Modern view on the therapy of chronic venous insufficiency with micronized purified flavonoid fraction

2020 ◽  
Vol 19 (4) ◽  
pp. 2592
Author(s):  
H. M. Kurginyan ◽  
V. V. Raskin
Keyword(s):  
Pharmaceutical Industry ◽  
Chronic Venous Insufficiency ◽  
Venous Insufficiency ◽  
Population Studies ◽  
Varicose Veins ◽  
Venous Diseases ◽  
High Prevalence ◽  
Important Direction ◽  
Micronized Purified Flavonoid Fraction ◽  
Flavonoid Fraction

The high prevalence of varicose veins has been established in numerous population studies. Currently, guidelines have been developed for the treatment of patients with varicose veins for various stages of chronic venous insufficiency. Nevertheless, despite the use of modern drugs, leg compression, surgical and other interventions, it is not possible to completely reverse the symptoms of venous insufficiency. The article is devoted to the analysis of micronized flavonoid purified fraction. The development of modern drugs for chronic venous diseases is an important direction in medicine. The creation of a drug pool manufactured InRussiais a priority in the development of the country’s pharmaceutical industry. The review presents data on the study of Detravenol (Russia), which is a combination of diosmin and hesperidin (micronized purified flavonoid fraction).

The Significance of Pain in Chronic Venous Disease and its Medical Treatment

2019 ◽  
Vol 17 (3) ◽  
pp. 291-297
Author(s):  
Djordje Radak ◽  
Igor Atanasijević ◽  
Mihailo Nešković ◽  
Esma Isenovic
Keyword(s):  
Varicose Veins ◽  
Compression Therapy ◽  
Interventional Therapy ◽  
Lifestyle Changes ◽  
Chronic Venous Disease ◽  
Venous Disease ◽  
Venous Ulcers ◽  
Venoactive Drugs ◽  
Micronized Purified Flavonoid Fraction ◽  
Flavonoid Fraction

Chronic venous disease (CVeD) is a highly prevalent condition in the general population, and it has a significant impact on quality of life. While it is usually manifested by obvious signs, such as varicose veins and venous ulcers, other symptoms of the disease are less specific. Among the other symptoms, which include heaviness, swelling, muscle cramps and restless legs, pain is the symptom that most frequently compels CVeD patients to seek medical aid. However, there is a substantial discrepancy between pain severity and clinically detectable signs of CVeD, questioned by several opposing studies. Further evaluation is needed to clarify this subject, and to analyse whether pain development predicts objective CVeD progression. </P><P> General management of CVeD starts with advising lifestyle changes, such as lowering body mass index and treating comorbidities. However, the mainstay of treatment is compression therapy, with the additional use of pharmacological substances. Venoactive drugs proved to be the drugs of choice for symptom alleviation and slowing the progression of CVeD, with micronized purified flavonoid fraction being the most effective one. Interventional therapy is reserved for advanced stages of the disease.

scholarly journals Current indications for phlebotropic therapy and its duration

2021 ◽  
Vol 18 (1) ◽  
pp. 13-23
Author(s):  
V. Yu. Bogachev ◽  
B. V. Boldin ◽  
P. Yu. Turkin ◽  
O. V. Dzhenina ◽  
A. Yu. Samenkov
Keyword(s):  
Clinical Practice ◽  
Systematized Review ◽  
Objective Control ◽  
Venoactive Drugs ◽  
Micronized Purified Flavonoid Fraction ◽  
Flavonoid Fraction ◽  
Severity Of The Disease ◽  
Guidelines And Standards ◽  
Specific Symptoms ◽  
Real Clinical Practice

Phlebotropic therapy is an important component of the pathogenetic treatment of chronic venous insufficiency (CVI) of the lower extremities. Venoactive drugs, which have proven their effectiveness and safety in a variety of studies, are widely represented in international and Russian clinical guidelines and standards. However, there is no consensus on the regulation of phlebotropic therapy and, above all, its duration in different clinical classes of CVI. In addition, there are no clear indications on the methods of treatment efficacy monitoring, which can be used in real clinical practice. The presented systematized review of the literature data on micronized purified flavonoid fraction not only reveals the possibilities of phlebotropic therapy of different clinical classes and forms of CVI, but also suggests effective regulations for the use of this drug in specific situations. The data concerning the efficacy of phlebotropic therapy in real clinical practice at the initial stages of CVI (C0s-C1s), in the treatment of C2s (varicose superficial veins with venospecific symptoms), C3 (chronic venous edema), C4 (trophic skin disorders), as well as in stages C5-C6 and C6r (venous trophic ulcers) are presented in details. In addition, the results of studies on the use of micronized purified flavonoid fraction in phlebosclerosing treatment are presented. The duration of phlebotropic therapy is in direct relation to the severity of the disease and the response to the ongoing treatment. The important role is played not only by personalization of treatment according to specific symptoms and syndromes, but also, if possible, by objective control of their dynamics.

scholarly journals CONSERVATIVE TREATMENT OF HEMORRHOIDS. AN ALTERNATIVE TO SURGICAL METHODS OR COMPONENTS? CHORUS PROGRAM RESULTS

2018 ◽  
pp. 27-35
Author(s):  
E. A. Zagryadskiy ◽  
A. M. Bogomazov ◽  
E. B. Golovko
Keyword(s):  
Surgical Treatment ◽  
Conservative Treatment ◽  
Clinical Manifestations ◽  
Entire Observation Period ◽  
Surgical Methods ◽  
Micronized Purified Flavonoid Fraction ◽  
Flavonoid Fraction ◽  
Observational Group ◽  
Grade Iii ◽  
Observation Period

OBJECTIVE. Determine the frequency of clinical manifestations of hemorrhoids and constipation in people seeking advice about hemorrhoids. In the course of the treatment of patients with hemorrhoids phlebotropic evaluate the effectiveness of therapy micronized purified flavonoid fraction (MPFF). MATERIALS AND METHODS. This multicenter study, including screening and observation part, which is part of the International Research «CHORUS» (Chronic venous and hemorrhoid diseases evaluation and scientific research), conducted in nine centers in different regions of Russia, 80 doctors of Coloproctology. In the screening group included 2668 patients who had investigated the incidence of constipation, as a risk factor for hemorrhoids. Conservative treatment, the foundation of which was, Moffitt therapy, received 1952 patients with stage I-IV hemorrhoids. Evaluating the effectiveness of the treatment was evaluated on the basis of a questionnaire. RESULTS. The questionnaire shows that constipation suffered - 766 (28,8 %) patients. Violation of defecation patterns and changes in stool consistency was observed in 1155 (43,9%) and 633 (25.5 %), respectively. At the same time, 288 (11,1 %) indicated a tendency to loose stools and diarrhea. Conservative treatment, the foundation of which is phlebotropic MPFF therapy conducted in patients of observational group has shown its efficiency in all grades of hemorrhoids. During the entire observation period of conservative treatment was effective in 1489 (76,3 %) patients. Surgical treatment was performed in 463 (23 %) patients grade I-IV hemorrhoids, the main part of patients with grade III -199 (43,1 %) and grade IV hemorrhoids - 68 (64,2 %). CONCLUSION. Conservative treatment of hemorrhoid disease, which is the basis on phlebotropic MPFF therapy, is effective at all stages of hemorrhoids, but in patients with grade III and grade IV disease requires surgical treatment.

scholarly journals Micronized purified flavonoid fraction in the treatment of hemorrhoidal disease

2021 ◽  
Author(s):  
Philippe Godeberge ◽  
Parvez Sheikh ◽  
Varut Lohsiriwat ◽  
Abel Jalife ◽  
Yury Shelygin
Keyword(s):  
Normal Activity ◽  
Hemorrhoidal Disease ◽  
Supporting Evidence ◽  
First Line ◽  
Adjunct Treatment ◽  
Anal Discharge ◽  
Venoactive Drugs ◽  
Micronized Purified Flavonoid Fraction ◽  
Flavonoid Fraction

Hemorrhoidal disease (HD) is common in adults. Treatment is largely conservative, although more invasive procedures may be required. Venoactive drugs such as micronized purified flavonoid fraction (MPFF) are widely used, but a recent and comprehensive review of supporting evidence is lacking. In acute HD, MPFF can reduce HD symptoms such as bleeding, pain, anal discomfort, anal discharge and pruritus. In patients undergoing surgery, postoperative adjunct MPFF consistently reduces pain, bleeding duration and use of analgesia. MPFF treatment is appropriate and effective both as a first-line conservative treatment and as a postoperative adjunct treatment. MPFF reduces the duration of hospital stay following surgery, facilitating a return to normal activity and improving quality of life. MPFF may also prevent HD recurrence.

The choice of excipients in the development of a soft dosage form of phleboprotective action containing a micronized flavonoid fraction

2021 ◽  
pp. 25-30
Author(s):  
Viktoriya Konstantinovna Maltseva ◽  
Eleonora Fedorovna Stepanova ◽  
Evgeniya Olegovna Kulichenko ◽  
Marina Sergeevna Makieva
Keyword(s):  
21St Century ◽  
Active Ingredient ◽  
Dosage Form ◽  
Sedentary Lifestyle ◽  
Varicose Veins ◽  
Semipermeable Membrane ◽  
Peg 400 ◽  
Flavonoid Fraction ◽  
Final Composition

Varicose veins are called one of the diseases of the 21st century, caused by a sedentary lifestyle and genetics. The purpose of this study was the development of ointment compositions containing the micronized flavonoid fraction and the study of the degree of release of the micronized fraction by the flavonoid from the ointment compositions with penetrating components. With the obtained ointment compositions, a complex of biopharmaceutical studies in vitro was carried out: release from ointment compositions by diffusion into a gelatin gel and dialysis through a semipermeable membrane, while the quality indicators of the ointment compositions were established. The conducted in vitro biopharmaceutical studies helped to determine the final composition of the ointment in relation to the auxiliary composition: active ingredient — 2%, PEG 1500:PEG 400 (7:3), propylene glycol — 1%.

Sign in / Sign up

Export Citation Format

Share Document